As Merck’s Keytruda Gains Momentum, Investors Look To The Future
This article was originally published in The Pink Sheet Daily
Executive Summary
Keytruda, already the first anti-PD-1 drug to market for melanoma, received FDA breakthrough therapy designation for an indication in lung cancer. The drug’s long-term potential – and upcoming data on a two-drug hepatitis C combo – helped to offset a decline in Merck’s third quarter sales.
You may also be interested in...
Emerging Markets Earnings: China A Star For Merck Key Product Sales
Merck looks for growth in key products across emerging markets to keep full-year earnings in check even as it revises down its forecast for revenues.
Safety Profile Of Merck’s Anti-PD-1 Keytruda Shines In FDA Labeling
Priced at $12,500/month, Keytruda will be ready to ship within one week of FDA approval for relapsed melanoma after failure of Yervoy and a BRAF inhibitor. Approval could spur interest in off-label use of PD-1 inhibitor as a first-line treatment.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.